[go: up one dir, main page]

CL2019002953A1 - Anticuerpo anti-pd-l1 y uso del mismo. - Google Patents

Anticuerpo anti-pd-l1 y uso del mismo.

Info

Publication number
CL2019002953A1
CL2019002953A1 CL2019002953A CL2019002953A CL2019002953A1 CL 2019002953 A1 CL2019002953 A1 CL 2019002953A1 CL 2019002953 A CL2019002953 A CL 2019002953A CL 2019002953 A CL2019002953 A CL 2019002953A CL 2019002953 A1 CL2019002953 A1 CL 2019002953A1
Authority
CL
Chile
Prior art keywords
antibodies
fully human
affinity
human anti
ability
Prior art date
Application number
CL2019002953A
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Sergei Barbashov
Alexey Repik
Mikhail Samsonov
Vasily Ignatiev
Shorena Archuadze
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of CL2019002953A1 publication Critical patent/CL2019002953A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DAN A CONOCER ANTICUERPOS ANTI-PD-L1 COMPLETAMENTE HUMANOS Y SUS APLICACIONES CORRESPONDIENTES. LOS ANTICUERPOS COMPLETAMENTE HUMANOS TIENEN LA CAPACIDAD DE ENLAZARSE ESPECÍFICAMENTE A PD-L1 DE HUMANO. LOS ANTICUERPOS SE OBTUVIERON AL EMPLEAR UNA TÉCNICA DE PROSPECCIÓN BASADA EN UNA GENOTECA DE DESPLIEGUE EN LEVADURA Y TAMBIÉN POR MEDIO DE LA MADURACIÓN DE LA AFINIDAD PARA MEJORAR ADICIONALMENTE SU AFINIDAD POR PD-L1. LOS ANTICUERPOS ANTI-PD-L1 COMPLETAMENTE HUMANOS DADOS A CONOCER MUESTRAN BUENA ESPECIFICIDAD, AFINIDAD Y ESTABILIDAD. ÉSTOS TIENEN LA CAPACIDAD DE MEJORAR LA ACTIVIDAD DE CÉLULAS T AL ENLAZARSE A CÉLULAS T ACTIVADAS, MIENTRAS QUE INHIBEN SIGNIFICATIVAMENTE EL CRECIMIENTO DE TUMORES. LOS ANTICUERPOS ANTI-PD-L1 COMPLETAMENTE HUMANOS DADOS A CONOCER SE PUEDEN USAR EN EL DIAGNÓSTICO Y EL TRATAMIENTO DE CÁNCERES RELACIONADOS CON PD-L1 Y OTRAS ENFERMEDADES ASOCIADAS.
CL2019002953A 2017-04-18 2019-10-16 Anticuerpo anti-pd-l1 y uso del mismo. CL2019002953A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18

Publications (1)

Publication Number Publication Date
CL2019002953A1 true CL2019002953A1 (es) 2020-01-10

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002953A CL2019002953A1 (es) 2017-04-18 2019-10-16 Anticuerpo anti-pd-l1 y uso del mismo.

Country Status (17)

Country Link
US (1) US20210115143A1 (es)
EP (1) EP3612565A4 (es)
JP (2) JP2020517239A (es)
KR (1) KR102323960B1 (es)
CN (1) CN110856446A (es)
AU (1) AU2018256392B2 (es)
BR (1) BR112019021828B1 (es)
CA (1) CA3059447A1 (es)
CL (1) CL2019002953A1 (es)
CO (1) CO2019012118A2 (es)
EA (1) EA201900443A1 (es)
MA (1) MA50038A (es)
MX (1) MX2019012461A (es)
MY (1) MY199319A (es)
PH (1) PH12019502302A1 (es)
SG (1) SG11201909041SA (es)
WO (1) WO2018195226A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
MX2021005594A (es) * 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
CN113646330A (zh) * 2018-11-14 2021-11-12 鲁比克治疗股份有限公司 工程化cd25多肽及其用途
JP7619941B2 (ja) 2018-11-14 2025-01-22 アイバイオ， インク． Ｃｄ２５抗体
CN109929037B (zh) 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
AU2020271467B2 (en) * 2019-04-11 2024-06-27 Scripps Korea Antibody Institute Antibodies against programmed death-ligand 1 and uses thereof
US11208486B2 (en) * 2019-04-26 2021-12-28 I-Mab Biopharma Us Limited Human PD-L1 antibodies
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
CA3187850A1 (en) * 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
WO2023046113A1 (zh) * 2021-09-24 2023-03-30 广东菲鹏制药股份有限公司 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
EP4658310A1 (en) 2023-01-30 2025-12-10 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2010077634A1 (en) * 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
EP4070818A3 (en) * 2014-01-06 2023-01-11 The Trustees of the University of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
WO2015127288A1 (en) * 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
MX2017011644A (es) * 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
RU2770590C2 (ru) * 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Антитела против pd-l1 и их варианты

Also Published As

Publication number Publication date
EA201900443A1 (ru) 2020-03-06
MX2019012461A (es) 2019-12-11
KR20190141169A (ko) 2019-12-23
BR112019021828A2 (pt) 2020-03-24
AU2018256392B2 (en) 2024-05-16
MY199319A (en) 2023-10-24
SG11201909041SA (en) 2019-11-28
AU2018256392A1 (en) 2019-10-17
JP2023025003A (ja) 2023-02-21
US20210115143A1 (en) 2021-04-22
KR102323960B1 (ko) 2021-11-10
WO2018195226A1 (en) 2018-10-25
EP3612565A1 (en) 2020-02-26
CN110856446A (zh) 2020-02-28
CO2019012118A2 (es) 2020-04-01
MA50038A (fr) 2020-07-08
JP2020517239A (ja) 2020-06-18
EP3612565A4 (en) 2021-06-16
CA3059447A1 (en) 2018-10-25
BR112019021828B1 (pt) 2022-09-20
PH12019502302A1 (en) 2020-09-21

Similar Documents

Publication Publication Date Title
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
CO2020000438A2 (es) Anticuerpos anti-ctla-4 y sus usos
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
CL2020002093A1 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl.
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
BR112018067458A2 (pt) anticorpos para tigit
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CY1124456T1 (el) Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων
PH12020500667A1 (en) Multispecific antibodies and use thereof
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX373790B (es) Anticuerpos humanos a ligando de muerte programada 1 (pd-l1).
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
EA202090204A1 (ru) Анти-cd137 антитела
BR112017001579A2 (pt) anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201691836A1 (ru) Антитела к mcam и соответствующие способы их применения
CL2023003182A1 (es) Receptores químericos de steap1 y métodos de uso de los mismos
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d